Amid rising coronavirus cases, the Serum Institute of India has written a letter to the Union Health Ministry seeking the inclusion of its Covid-19 vaccine, Covovax, on the CoWIN portal as a heterologous booster dose for adults, official sources said on Monday.
The letter was written by Prakash Kumar Singh, Director, Serum Institute of India, on March 27, they said.
Last month, the Covid-19 Working Group, headed by Dr. N. K. Arora, also recommended to the health ministry the inclusion of Covovax on the CoWIN portal as a heterologous booster dose for adults who have been vaccinated with two doses of either Covishield or Covaxin.
The Drugs Controller General of India had approved the market authorization for Covovax for those who had been administered two doses of either Covishield or Covaxin. Also, Covovax has been approved by the World Health Organisation and the U.S. Food and Drug Administration.
The DCGI had approved Covovax for restricted use in emergency situations in adults on Dec. 28, 2021; in the 12–17 age group on March 9, 2022; and in the 7–11 age group on June 28, 2022, subject to certain conditions.
Covovax is manufactured through a technology transfer from U.S.-based vaccine maker Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation. It was granted an emergency use listing by the WHO on Dec.17, 2021.
In August 2020, Novavax Inc. announced a licence agreement with the SII for the development and commercialisation of NVX-CoV2373, its Covid-19 vaccine candidate, in India and other low- and middle-income countries.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.